<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487030</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-1643</org_study_id>
    <nct_id>NCT02487030</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</brief_title>
  <official_title>A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>Egypt: Ministry of Health and Population</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir
      (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in Egyptian adults
      with chronic genotype 4 hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of any adverse event leading to permanent discontinuation of study drug</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR4 and SVR24 are defined as HCV RNA &lt; LLOQ 4 and 24 weeks after the last dose of study drug, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with virologic failure</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Virologic failure is defined as
On-treatment virologic failure
confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ, while on treatment (ie, breakthrough),
confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound),
HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse)
Relapse
HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>LDV/SOF 8 wk TN (Cohort 1, Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF for 8 weeks (treatment-naive (TN))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF+RBV for 8 weeks (treatment-naive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF 12 wk TN (Cohort 1, Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF for 12 weeks (treatment-naive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF+RBV for 12 weeks (treatment-naive)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF 12 wk TE (Cohort 3, Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF for 12 weeks (treatment-experienced)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LDV/SOF+RBV for 12 weeks (treatment-experienced)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF</intervention_name>
    <description>LDV/SOF (90/400 mg) FDC tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF 8 wk TN (Cohort 1, Group 1)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)</arm_group_label>
    <arm_group_label>LDV/SOF 12 wk TN (Cohort 1, Group 3)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 2)</arm_group_label>
    <arm_group_label>LDV/SOF 12 wk TE (Cohort 3, Group 1)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)</arm_group_label>
    <other_name>Harvoni®</other_name>
    <other_name>GS-5885/GS-7977</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>RBV tablets administered orally in a divided daily dose based on weight (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 2)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent.

          -  Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy

          -  HCV genotype 4 at screening

          -  HCV treatment naive or prior participation in this study or study GS-US-334-0138
             (Cohorts 1 and 2 only)

          -  Cohort 3 only: HCV treatment-experienced (previously received therapy for HCV
             infection with an interferon (IFN)-containing regimen, with or without RBV and/or an
             HCV NS3/NS4A protease inhibitor (PI)

          -  Body mass index (BMI) ≥ 18 kg/m^2

          -  Screening laboratory values within defined thresholds

          -  Use of effective protocol-approved contraception methods

        Exclusion Criteria:

          -  History of clinically-significant illness or any other major medical disorder that
             may interfere with treatment, assessment or compliance with the protocol

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Pregnant or nursing females or male with pregnant female partner

          -  Clinically-relevant drug or alcohol abuse within 12 months of screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Kersey, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Study Team</last_name>
    <email>337-1643@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Mansoura</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shebeen El-Kom</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 9, 2015</lastchanged_date>
  <firstreceived_date>June 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV genotype 4 (GT-4)</keyword>
  <keyword>HCV</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct Acting Antiviral</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>GS-7977</keyword>
  <keyword>GS-5885</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>ledipasvir</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Liver Diseases</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Antiviral Agents</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
